Renascience Inc. (TYO:4889)

Japan flag Japan · Delayed Price · Currency is JPY
1,533.00
+37.00 (2.47%)
Jun 2, 2025, 3:30 PM JST
316.58%
Market Cap 19.49B
Revenue (ttm) 132.00M
Net Income (ttm) 113.00M
Shares Out 12.71M
EPS (ttm) 8.89
PE Ratio 172.45
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 873,300
Average Volume 2,956,350
Open 1,520.00
Previous Close 1,496.00
Day's Range 1,460.00 - 1,550.00
52-Week Range 263.00 - 2,474.00
Beta 2.41
RSI 57.68
Earnings Date May 14, 2025

About Renascience

Renascience Inc. engages in the development and commercialization of pharmaceuticals and medical devices in Japan. The company is developing RS5614, a PAI-1 inhibitor product candidate for use in the treatment of chronic myeloid leukemia, malignant melanoma, non-small cell lung cancer, novel coronavirus infections, and FGF23-related hypophosphatemic rickets that is in Phase 3 clinical trials; RS5441, a PAI-1 inhibitor for use in dermatological diseases that is in Phase I clinical trials; and RS8001, a water-soluble vitamin for use in the treatm... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 4
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4889
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.